Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 13/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3309265 | 1.00 | F10 (0.51) | F10MAPK1F2KMT2ALMNA | |
| SCHEMBL8251746 | 0.81 | MAPK1 (0.46) | F10MAPK1F2TSHR | |
| SCHEMBL8259245 | 0.81 | F10 (0.55) | F10MAPK1F2KMT2ALMNA | |
| SCHEMBL3551408 | 0.80 | F10 (0.59) | F10MAPK1F2KMT2ALMNA | |
| SCHEMBL3556784 | 0.80 | F10 (0.59) | F10MAPK1F2KMT2ALMNA | |
| SCHEMBL3303858 | 0.78 | F10 (0.50) | F10F2 | |
| SCHEMBL3303853 | 0.78 | F10 (0.50) | F10F2 | |
| SCHEMBL3450499 | 0.77 | F10 (0.47) | F10MAPK1F2KMT2ALMNA | |
| Hydrochloric Acid SCHEMBL3450496 | 0.76 | F10 (0.46) | F10MAPK1F2KMT2ALMNA | |
| SCHEMBL3448759 | 0.73 | F10 (0.51) | F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309542-B2 | Substituted pyrrolidine amides, the production thereof, and the use thereof as medications | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-13 | — | — | US | disclosed |
| EP-2132193-B1 | SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS | BOEHRINGER INGELHEIM INT (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-20100099664-A1 | SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-22 | — | — | US | disclosed |
| EP-2132193-A1 | SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS | Boehringer Ingelheim International GmbH (DE) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008116881-A1 | SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099664-A1 | SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS | DDC, GLS, UROD | F10 2924/4885MAPK1 2494/4885F2 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.